Ontology highlight
ABSTRACT:
SUBMITTER: Leipold DD
PROVIDER: S-EPMC6284592 | biostudies-literature | 2018 Nov-Dec
REPOSITORIES: biostudies-literature
Leipold Douglas D DD Figueroa Isabel I Masih Shabkhaiz S Latifi Brandon B Yip Victor V Shen Ben-Quan BQ Dere Randall C RC Carrasco-Triguero Montserrat M Lee M Violet MV Saad Ola M OM Liu Luna L He Jintang J Su Dian D Xu Keyang K Vuillemenot Brian R BR Laing Steven T ST Schutten Melissa M Kozak Katherine R KR Zheng Bing B Polson Andrew G AG Kamath Amrita V AV
mAbs 20181002 8
Few treatment options are available for acute myeloid leukemia (AML) patients. DCLL9718A is an antibody-drug conjugate that targets C-type lectin-like molecule-1 (CLL-1). This receptor is prevalent on monocytes, neutrophils, and AML blast cells, and unlike CD33, is not expressed on hematopoietic stem cells, thus providing possible hematopoietic recovery. DCLL9718A comprises an anti-CLL-1 IgG1 antibody (MCLL0517A) linked to a pyrrolobenzodiazepine (PBD) dimer payload, via a cleavable disulfide-la ...[more]